Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Flotetuzumab as salvage therapy for primary induction failure and early AML

Ibrahim Aldoss • 11 Feb 2021
TCT 2021
Acute Myeloid Leukemia Leukemia Flotetuzumab

Ibrahim Aldoss, MD, City of Hope National Medical Center, Duarte, CA, discusses updated results of the first-in-human study of flotetuzumab, an investigational CD123 x CD3 bi-specific product currently in development for patients with acute myeloid leukemia (AML). Flotetuzumab has demonstrated encouraging activity in patients with primary induction failure and early relapse AML, which represents a population with poor prognosis and unmet need. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Ibrahim Aldoss

The future of T-cell engagers and CARs in acute lymphoblastic leukemia
12:16
The future of T-cell engagers and CARs in acute lymphoblastic leukemia
Bijal Shah et al. • 25 Apr 2026
AUGMENT-101 trial: revumenib in patients with R/R KMT2Ar acute leukemia
4:06
AUGMENT-101 trial: revumenib in patients with R/R KMT2Ar acute leukemia
Ibrahim Aldoss • 11 Dec 2023
Outcomes of alloHCT in adults with Ph-like ALL
5:05
Outcomes of alloHCT in adults with Ph-like ALL
Ibrahim Aldoss • 11 Feb 2021

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals